Inactive Instrument

MolMed S.p.A.

Equities

MLM

IT0001080248

Biotechnology & Medical Research

Molmed S.P.A. Reports Earnings Results for the Third Quarter Ended September 30, 2019

November 11, 2019

MolMed S.P.A. Announced earnings results for the third quarter ended September 30, 2019. For the third quarter, the company announced total revenue was EUR 8.511 million compared to EUR 7.300 million a year ago. Operating loss was EUR 444,000 compared to EUR 1.777 million a year ago. Net loss was EUR 487,000 compared to EUR 1.788 million a year ago. For the nine months, total revenue was EUR 24.886 million compared to EUR 20.012 million a year ago. Operating loss was EUR 2.341 million compared to EUR 4.628 million a year ago. Net loss was EUR 2.409 million compared to EUR 4.873 million a year ago.

Latest news about MolMed S.p.A.

Genenta Science S.p.A. and AGC Biologics S.p.A. Enter into A Development and Manufacturing Services Agreement	02/23/02	CI
AGC Biologics and W.L. Gore & Associates Collaborate on New Protein A-Based Purification Technology and Contract Manufacturing Services for Antibody Therapies	12/22/12	CI
RoosterBio and AGC Biologics Announce Collaboration to Accelerate Manufacturing of Cell and Exosome Therapies	16/22/16	CI
AGC Biologics Partners with BioNTech SE to Further Supply Plasmid DNA Starting Material for the Pfizer-BioNTech COVID-19 vaccine, at AGC’s Heidelberg, Germany facility	07/21/07	CI
MolMed Announces Transition of Luca Alberici from the Role of Chief Business Officer	12/20/12	CI
MolMed S.p.A.(BIT:MLM) dropped from S&P Global BMI Index	03/20/03	CI
AGC Inc. completed the acquisition of 93.2% in MolMed S.p.A. from Finanziaria d'investimento Fininvest S.p.A. and others for approximately €220 million.	24/20/24	CI
Orchard Therapeutics and MolMed Announce Extension of Gene Therapy Manufacturing Collaboration	09/20/09	CI
AGC : Italy to use vetting powers in Molmed acquisition by Japan's AGC	07/20/07	RE
AGC Inc. entered into an agreement to acquire MolMed S.p.A. from Finanziaria d'investimento Fininvest S.p.A. and others for approximately €240 million.	17/20/17	CI
Molmed S.P.A. Reports Earnings Results for the Full Year Ended December 31, 2019	09/20/09	CI
Molmed S.P.A. Reports Earnings Results for the Third Quarter Ended September 30, 2019	11/19/11	CI
Molmed S.P.A. Reports Earnings Results for the Half Year Ended June 30, 2019	29/19/29	CI
Molmed S.P.A. Reports Earnings Results for Third Quarter and Nine Months Ended September 30, 2018	12/18/12	CI
MolMed S.p.A. and AbCheck s.r.o. Sign A Three-Year Master Agreement for the Development of New Cars Targeting Novel Tumor Antigens	28/18/28	CI
MolMed S.p.A. Announces Earnings Results for the First Quarter Ended March 31, 2018	11/18/11	CI
MolMed S.p.A. Reports Earnings Results for the Full Year Ended of December 31, 2017	09/18/09	CI
Molmed S.P.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2017	06/17/06	CI
MolMed S.p.A. announced that it has received funding from Société Générale Capital Partenaires SAS, SCR	21/17/21	CI
MolMed S.p.A. Announces Earnings Results for the Six Months Ended June 30, 2017	27/17/27	CI
MolMed S.p.A. and TTY Biopharm Company Ltd Announce Exclusive License and Distribution Agreement	03/17/03	CI
MolMed S.p.A. Reports Earnings Results for the First Quarter Ended March 31, 2017	08/17/08	CI
Megapharm Enters into Distribution and Licensing Agreement with MolMed for Zalmoxis	01/17/01	CI
MolMed S.p.A. Reports Earnings Results for the Full Year Ended of December 31, 2016	06/17/06	CI
MolMed S.p.A. announced that it expects to receive funding from Société Générale Capital Partenaires SAS, SCR	16/16/16	CI

Chart MolMed S.p.A.

Duration

Period

More charts

Company Profile

Molecular Medicine SpA (MolMed) is an Italy-based company engaged in the medical biotechnology sector. The Company is active in the research, development and clinical validation of therapies for the treatment of cancer. The Company's activities include identification and development of bio-pharmaceuticals reducing the tumor mass and slowing down its growth, as well as the development of selective therapies to eliminate residual tumor tissue. MolMed's pipeline comprises two main investigational anticancer therapies: TK, which is a cell-based therapy for the treatment of leukemia, and NGR-hTNF, which is a biological drug targeting tumor blood vessels for the treatment of solid tumors. MolMed develops, conducts and validates custom studies, creating testing procedures and addressing the test specifications required for cell-based therapies. It is also active in the production of cell-based medicinal products used in clinical trials and drug development of cell-based therapies.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+24.30%	46.71B
LONZA GROUP AG	+48.83%	41.8B
IQVIA HOLDINGS INC.	-1.01%	41.52B
CELLTRION, INC.	-5.86%	29.55B
ICON PUBLIC LIMITED COMPANY	+11.21%	25.78B
ALNYLAM PHARMACEUTICALS, INC.	-20.89%	19.26B
BIO-TECHNE CORPORATION	+3.02%	12.14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.20%	12.08B
MEDPACE HOLDINGS, INC.	+30.57%	11.98B

Other Biotechnology & Medical Research